/ARDX
ARDX Stock - Ardelyx, Inc.
Healthcare|BiotechnologyNASDAQ
$5.68+0.00%
+$0.00 (+0.00%) • Dec 19
82
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.70
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.98
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+76.1%upside
Target: $10.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ARDX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.62 – $5.74
TARGET (TP)$10.00
STOP LOSS$5.23
RISK/REWARD1:9.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.55
52W High$6.78
52W Low$3.21
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $333.62M | $124.46M | $52.16M | $10.10M | $7.57M |
| Gross Profit | $283.06M | $106.66M | $48.04M | $9.10M | $7.43M |
| Gross Margin | 84.8% | 85.7% | 92.1% | 90.1% | 98.1% |
| Operating Income | $-27,950,000 | $-63,276,000 | $-63,759,000 | $-154,346,000 | $-90,780,000 |
| Net Income | $-39,136,000 | $-66,067,000 | $-67,207,000 | $-158,165,000 | $-94,313,000 |
| Net Margin | -11.7% | -53.1% | -128.9% | -1566.5% | -1245.7% |
| EPS | $-0.17 | $-0.30 | $-0.42 | $-1.52 | $-1.05 |
Company Overview
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
2
17%
Buy / Outperform
7
58%
Hold / Neutral
3
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
9 Bullish3 Neutral/Bearish
Price Targets
$9
Average Target
↑ 64.5% Upside
Now
$1
Low
$9
Average
$14
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 3rd 2025 | Raymond James | Resumed | Strong Buy | $14 |
| June 18th 2025 | H.C. Wainwright | Resumed | Buy | $10 |
| May 2nd 2025 | Raymond James | Downgrade | Outperform | $11 |
| March 7th 2025 | Ladenburg Thalmann | Resumed | Buy | - |
| March 4th 2025 | BTIG Research | Initiation | Buy | $14 |
| November 11th 2024 | H.C. Wainwright | Downgrade | Neutral | $5.5← $11 |
| July 2nd 2024 | Piper Sandler | Downgrade | Neutral | $7← $15 |
| April 5th 2024 | Leerink Partners | Initiation | Outperform | $14 |
| December 18th 2023 | Raymond James | Initiation | Strong Buy | $12 |
| September 7th 2023 | H.C. Wainwright | Initiation | Buy | $9 |
| August 25th 2023 | Cantor Fitzgerald | Upgrade | Overweight | $10← $5 |
| March 3rd 2023 | Wedbush | Upgrade | Outperform | $6← $3 |
| November 17th 2022 | Piper Sandler | Upgrade | Overweight | $8← $3 |
| May 6th 2022 | Cantor Fitzgerald | Downgrade | Neutral | $1← $7 |
Earnings History & Surprises
ARDXBeat Rate
50%
Last 18 quarters
Avg Surprise
+351.9%
EPS vs Estimate
Beats / Misses
9/7
2 met exactly
Latest EPS
$-0.00
Q4 2025
EPS Surprise History
Q1 24
-33.3%
$-0.12vs$-0.09
Q2 24
+15.4%
$-0.11vs$-0.13
Q3 24
+30.0%
$-0.07vs$-0.10
Q4 24
+93.1%
$-0.00vs$-0.05
Q1 25
0.0%
$0.02vs$0.02
Q2 25
-70.0%
$-0.17vs$-0.10
Q3 25
+38.5%
$-0.08vs$-0.13
Q4 25
+93.3%
$-0.00vs$-0.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $0.02 | — | — | — |
Q4 2025 | Oct 30, 2025 | $-0.06 | $-0.00 | +93.3% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $-0.13 | $-0.08 | +38.5% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-0.10 | $-0.17 | -70.0% | ✗ MISS |
Q1 2025 | Feb 20, 2025 | $0.02 | $0.02 | 0.0% | = MET |
Q4 2024 | Oct 31, 2024 | $-0.05 | $-0.00 | +93.1% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-0.10 | $-0.07 | +30.0% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.13 | $-0.11 | +15.4% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.09 | $-0.12 | -33.3% | ✗ MISS |
Q4 2023 | Oct 31, 2023 | $-0.11 | $0.03 | +127.3% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-0.12 | $-0.08 | +33.3% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.11 | $-0.13 | -18.2% | ✗ MISS |
Q1 2023 | Mar 2, 2023 | $0.00 | $0.06 | +6085.6% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.17 | $-0.14 | +17.6% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.19 | $-0.19 | 0.0% | = MET |
Q2 2022 | May 5, 2022 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.25 | $-0.31 | -24.0% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.34 | $-0.42 | -23.5% | ✗ MISS |
Q3 2021 | Aug 13, 2021 | $-0.36 | $-0.45 | -25.0% | ✗ MISS |
Latest News
Ardelyx Presents Data, Including Results From First Real-World Study Of XPHOZAH, At ASN Kidney Week
➖ NeutralBenzinga•Nov 7, 2025, 09:06 PM
Piper Sandler Maintains Neutral on Ardelyx, Raises Price Target to $10
➖ NeutralBenzinga•Nov 4, 2025, 04:40 PM
Ardelyx Files For Mixed Shelf; Size Not Disclosed
➖ NeutralBenzinga•Nov 3, 2025, 10:32 PM
Citigroup Maintains Buy on Ardelyx, Raises Price Target to $11
📈 PositiveBenzinga•Nov 3, 2025, 08:37 PM•Also:
TD Cowen Maintains Buy on Ardelyx, Raises Price Target to $10
📈 PositiveBenzinga•Oct 31, 2025, 06:02 PM
Ardelyx shares are trading higher after the company reported better-than-expected Q3 sales results.
📈 PositiveBenzinga•Oct 31, 2025, 01:14 PM
Ardelyx shares are trading higher after the company reported better-than-expected Q3 sales results.
📈 PositiveBenzinga•Oct 30, 2025, 08:45 PM
Ardelyx Q3 Sales $110.329M Beat $100.878M Estimate
📈 PositiveBenzinga•Oct 30, 2025, 08:01 PM
Ardelyx Presents Data Supporting Retainagogue, IBSRELA At ACG Annual Scientific Meeting, In Phoenix
📈 PositiveBenzinga•Oct 28, 2025, 12:02 PM
Ardelyx Announces It Will Present New Data Supporting Its Kidney Disease Drug Xphozah At American Society Of Nephrology's Kidney Week 2025 November 5–9 In Houston, Texas
📈 PositiveBenzinga•Oct 21, 2025, 12:04 PM
Ardelyx Appoints Sue Hohenleitner CFO, Effective Nov. 4
➖ NeutralBenzinga•Oct 13, 2025, 12:33 PM
Ardelyx appoints Edward Conner as Chief Medical Officer
➖ NeutralSeeking Alpha•Aug 4, 2025, 09:46 PM
Ardelyx spike attributed to Xphozah legal update
📈 PositiveSeeking Alpha•Jul 2, 2025, 05:38 PM
Frequently Asked Questions about ARDX
What is ARDX's current stock price?
Ardelyx, Inc. (ARDX) is currently trading at $5.68 per share. The stock has moved +0.00% today.
What is the analyst price target for ARDX?
The average analyst price target for ARDX is $10.00, based on 1 analyst.
What sector is Ardelyx, Inc. in?
Ardelyx, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ARDX's market cap?
Ardelyx, Inc. has a market capitalization of $1.36 billion, making it a small-cap company.
Does ARDX pay dividends?
No, Ardelyx, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBCRX
BioCryst Pharmaceuticals, Inc.
$7.41
Mkt Cap: $1.6B
MAZE
Maze Therapeutics, Inc.
$41.71
Mkt Cap: $2.0B
NTLA
Intellia Therapeutics, Inc.
$9.23
Mkt Cap: $1.0B
PHVS
Pharvaris N.V.
$25.59
Mkt Cap: $1.7B
STOK
Stoke Therapeutics, Inc.
$31.96
Mkt Cap: $1.8B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
TRVI
Trevi Therapeutics, Inc.
$13.01
Mkt Cap: $1.7B
UPB
Upstream Bio, Inc.
$29.35
Mkt Cap: $1.6B
WVE
Wave Life Sciences Ltd.
$15.98
Mkt Cap: $2.6B
ZYME
Zymeworks Inc.
$27.23
Mkt Cap: $2.0B
Explore stocks similar to ARDX for comparison